Kornimate/medical-research-clean huggingface dataset:
application of mi-bci combined with tdcs in early rehabilitation after anterior cruciate ligament reconstruction

Conditions: Anterior Cruciate Ligament Injuries

Summary: to recover lower-limb motor function is a primary goal for rehabilitation after anterior cruciate ligament (acl) reconstruction. although quantitative testing and questionnaire evaluation provide a lot of valuable information, while functional magnetic resonance imaging (fmri) provides a powerful method to assess functional connectivity (fc) involved in motor function recovery before and after receiving a novel combined rehabilitation training. however, our understanding of the fc changes during early rehabilitation after acl reconstruction is partial and incomplete.

acl has become one of the most common and easily damaged knee ligaments in sports and military training affecting young and active people. the extensive interest in acl ruptures is related to the subsequent articular degeneration and severe dysfunction, resulting in skeletal muscle functional limitations not only in athletics but also in daily living. thus, restoring lower limb motor function and stability has become the primary goal after acl reconstruction (aclr). moreover, the newest study has indicated that increased neural activity may reflect central neuroplastic strategies to preserve motor functionality after aclr\[1\]. postsurgical rehabilitation guidelines for the orthopedic clinician recommended a common treatments for aclr patients\[2\]; however, because of long time consuming and poor compliance, which are difficult to get patient recognition, it is very urgent to find a safe, effective and easy conduct and alternative therapy. transcranial direct-current stimulation (tdcs) is a non-invasive technique of brain stimulation that has potential for clinical utility in neurorehabilitation, and could improve the lower excitability, muscle strength and dynamic balance by acting on the primary motor cortex\[3\]. for another, motor imagery based brain-computer interface (mi-bci) based neuro rehabilitation paradigms have emerged as a novel iatrotechnics on motor function and brain function recovery\[4\]. however, it is little explored whether the clinical application of mi-bci therapy combined with tdcs could be effective for early rehabilitation after aclr patients. this case report would explore the efficacy and neuromechanism for the aclr patient treated with mi-bci training combined with tdcs. bold-fmri was performed before and after four weeks' treatment.

Eligibility criteria:
inclusion criteria: * duration of anterior cruciate ligament injury: 3-12 months * must bet acceptted anterior cruciate ligament reconstruction exclusion criteria: * the affected limb has severe ligament and meniscus damage * contralateral lower extremity sports injury * other medical conditions, such as severe disc herniation, are not eligible for the test

Keywords: fmri mi-bci tdcs after anterior cruciate ligament
renal denervation in treatment resistant hypertension

Conditions: Hypertension

Summary: the purpose of this double-blind, randomized and sham controlled study is to investigate the blood pressure lowering effect of renal denervation by catheter based ablation in the renal arteries in patients with milder forms of treatment resistant hypertension. the effect on blood pressure will be evaluated by 24-hour ambulatory blood pressure measurements at baseline and after 3 and 6 months of follow up. secondary endpoint evaluation comprises hemodynamic assessment by applanation tonometry and the cold pressor response.


Eligibility criteria:
inclusion criteria: * systolic daytime (24 hour-ambulatory blood pressure measurement) \> 135 mmhg and \< 145 mmhg. * stable (for at least 1 month and with no planned changes for the next 6 months) antihypertensive therapy with at least 3 antihypertensive drugs, including a diuretic. * documented adherence to present antihypertensive therapy exclusion criteria: * pregnancy * non compliance * heart failure (nyha class iii-iv) * lv ejection fraction \< 50 % * renal insufficiency (egfr\<30 ml/min) * unstable coronary heart disease * coronary intervention within 6 months * myocardial infarction within 6 months * claudication * orthostatic syncope within 6 months * secondary hypertension (except ckd) * significant valvular heart disease * clinically significant biochemical abnormalities (electrolytes, haemoglobin, hepatic function, thyroid) * second and third degree av block * macroscopic haematuria * renal artery anatomy not suitable for renal artery ablation (stenosis, diameter \< 4 mm, length \< 2 cm or severe calcifications) * moderate/severe obstructive sleep apnoea (ahi \> 15) if cpap treatment has not been attempted

Keywords: treatment resistant hypertension renal denervation
a trial of ferumoxytol for the treatment of iron deficiency anemia in pediatric participants with nondialysis-dependent chronic kidney disease

Conditions: Iron Deficiency Anemia; Nondialysis-dependent Chronic Kidney Disease

Summary: study evaluating the efficacy and safety of intravenous (iv) ferumoxytol compared with oral iron for the treatment of pediatric participants with chronic kidney disease (ckd).

study amag-fer-ckd-252 was a study evaluating the efficacy and safety of iv ferumoxytol in pediatric participants with nondialysis-dependent ckd. study amag-fer-ckd-251 (nct01155375) was a study evaluating the efficacy and safety of iv ferumoxytol in pediatric participants with dialysis-dependent ckd. due to significant challenges with enrollment for both studies, study amag-fer-ckd-252 was combined with study amag-fer-ckd-251 and enrollment continued under study amag-fer-ckd-251. the enrollment number (n=14) includes the number of participants for both amag-fer-ckd-251 and amag-fer-ckd-252 studies, combined. participants were enrolled by age cohorts in a stepwise manner following a safety review by the data safety monitoring board of 1 age cohort prior to enrollment of a subsequent age cohort, with progression from oldest to youngest. randomization was stratified by the following age cohorts: 12 to \<18 years, 6 to \<12 years, 2 to \<6 years, and 6 months to \<2 years.

Eligibility criteria:
key inclusion criteria for this study include: 1. males or females 6 months to \<18 years of age 2. nondialysis dependent ckd, including kidney transplant recipients 3. has iron deficiency anemia defined as: a) hemoglobin level \<11.0 grams (g)/deciliter (dl) and b) transferrin saturation level \<20% 4. female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study key exclusion criteria for this study include: 1. history of allergy to either oral or iv iron 2. allergy to two or more classes of drugs 3. female participants who are pregnant, intend to become pregnant, are breastfeeding, within 3 months postpartum, or have a positive serum/urine pregnancy test 4. hemoglobin level ≤7.0 g/dl 5. serum ferritin level \>600 nanograms/milliliter

Keywords: iron deficiency anemia feraheme ferumoxytol ckd pediatric nondialysis-dependent
effectiveness and safety of probiotic in regulating chronic constipation

Conditions: Chronic Constipation

Summary: to evaluate the effectiveness and safety of the use of probiotics as food supplements in regulating the intestinal habit of subjects with chronic constipation, in comparison with placebo.


Eligibility criteria:
inclusion criteria: patients with chronic constipation (duration more than 3 months with less than three bowel movements per week and/or bristol scale 1 and 2). exclusion criteria: 1. diabetic patients. 2. pregnant patients. 3. breastfeeding patients. 4. patients requiring antibiotic treatment. 5. patients requiring treatment with tricyclic antidepressants, antiepileptics, antihistamines, antiparkinsonians, antipsychotics, antispasmodics, verapamil, monoamine oxidase inhibitors, opiates, sympathomimetics, antacids (with aluminum and calcium), antidiarrheals and nonsteroidal anti-inflammatory drugs. 6. patients who change the type of diet during the study. 7. patients with allergy or intolerance to any of the ingredients in the formulation of the product under study. 8. subjects with a history of pharmacological, alcoholic, or other substance abuse, or other factors that limit their ability to cooperate during the study. 9. excessive alcohol consumption (\>3 glasses of wine or beer/day). 10. subjects whose condition does not make them eligible for the study, according to the researcher.

Keywords: probiotics；chronic constipation
dynamic ultrasound of the calf muscles after stroke

Conditions: Stroke; Gait Disorders, Neurologic

Summary: muscle behaviour of calf muscles can be studied during dynamic conditions using dynamic ultrasound. in particular, the medial gastrocnemius is suitable for measurements with dynamic ultrasound due to its superficial location. with this measurement technique, the muscle behavior during walking can be observed gaining insight into the mechanism of action of this muscle during a functional task. this technique has already been used in other populations (such as children with cerebral palsy) but not yet in individuals after a stroke. therefore, the aim of this study is to assess the muscle behavior of the medial gastrocnemius during walking in persons after stroke. there are 3 concrete objectives of the current study: 1. is the technique feasible to perform in persons after stroke? 2. does the use of the dynamic echoprobe change gait patterns? 3. can differences between persons after stroke and healthy controls be detected? this data can be used as pilot data for project applications in the future that will allow to design larger studies. therefore, 10 stroke patients and 10 age- and gender-matched healthy controls will walk on a treadmill for 3x2 minutes after a familiarisation period of 6 minutes. during 1 x 2 minutes, subjects will walk without using the dynamic ultrasound. this recording aims to measure the normal gait pattern of the subjects. during the other 2x2 minutes, subjects will walk using the dynamic ultrasound at 2 different locations on the calf. once with the ultrasound probe on the centre of the muscle belly to visualise muscle fibre bundles and once on the muscle tendon transition, from which muscle belly and tendon length can be derived. the use of ultrasound or not will be randomized to exclude the effect of fatigue on the outcome measures.


Eligibility criteria:
stroke group inclusion criteria * stroke adults * no other neurologic conditions * ability to walk independently on a treadmill exclusion criteria * wearing ankle foot orthosis that inhibit the assessment * had lower limb surgery in the past healthy volunteers inclusion criteria - healthy adults exclusion criteria * suffering from any neurological condition * had lower limb surgery in the past
effects of nmes in critically ill patients

Conditions: Mechanical Ventilation Complication; Muscle Weakness Condition; Covid19

Summary: muscle wasting occurred early and rapidly in critically ill patients. early therapeutic strategies to either maintain muscle structure and function should be encouraged. neuromuscular electrical stimulation (nmes) is an attractive intervention to maintain muscle mass and strength in critically ill patients during the first week of icu stay. this study will test the hypothesis that the number of contraction per day evoked by nmes in the first two weeks of illness may influence in muscle wasting, with beneficial effects on the physical and functional status in mechanically ventilated patients.

patients with prolonged mechanical ventilation require deep sedation and mechanical ventilation, factors predisposing to the development of skeletal muscle wasting and acute muscle atrophy. strategies to attenuate this process must be used. the neuromuscular electrostimulation (nmes) leads to the application of electrical currents in the skin aiming at muscle contraction, has beneficial effects for the population of critical patients. however, the number of contractions induced by nmes to attenuate the loss of muscle mass in this population is not yet established. this randomized controlled trial with 120 patients that will be randomized to one of the 3 study groups: 100 continuous daily contractions (100cd), 50 continuous daily contractions (50cd) and control group. muscle thickness, nmes-induced strength, and clinical and functional parameters at the time of discharge from the icu and hospital discharge will be assessed daily. the results of this project will provide an important contribution to the understanding of the mechanisms associated with nmes treatment as a tool to minimize the effects of muscle disuse, as well as providing scientific support for the clinical use of this resource in the treatment in the light of the policies' health system.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * intubated and expected to remain invasively mechanically ventilated the day after tomorrow * laboratory confirmed covid-19 (diagnosis of sars-cov-2 via reverse transcriptase polymerase chain reaction as per the world health organization protocol or by nucleic acid based isothermal amplification) exclusion criteria: * dependent for activities of daily living in the month prior to current icu admission (gait aids are acceptable). * documented cognitive impairment. * proven or suspected spinal cord injury or other neuromuscular disease that will result in permanent or prolonged weakness (not including icu acquired weakness) * death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision maker are not committed to full active treatment * pregnancy * patients with unstable fractures in the vertebral column and lower limbs.

Keywords: muscular atrophy electric stimulation therapy intensive care units
education-based i̇ntervention program for persons with chronic obstructive pulmonary disease (ebipcopd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: obstructive pulmonary disease(copd) treatment, leading to the role of nurses to become more and more important. an education-based intervention program(ebip) consists of several steps that aim to achieve better health outcomes through guidingcopd patients to reduce dyspnea symptoms and improve chronic self-care management skills. the aim of this study is to evaluate the dyspnea and chronic self-care management outcomes of ebip compared to routine care. research hypotheses: h0: ebip has no effect on dyspnea or chronic self-care management in copd patients. h1: ebip effects dyspnea outcomes of copd patients. h2: ebip effects chronic self-care management outcomes of copd patients.

abstract: background:non-pharmacological interventions are a valuable aspect of chronic obstructive pulmonary disease(copd) treatment, leading to the role of nurses to become more and more important. an education-based intervention program(ebip) consists of several steps that aim to achieve better health outcomes through guidingcopd patients to reduce dyspnea symptoms and improve chronic self-care management skills. the aim of this study is to evaluate the dyspnea and chronic self-care management outcomes of ebip compared to routine care. method:a total of 61 stage ii copd patients that were hospitalized and treated in the month of january 2019 in a university hospital were selected for the study, who had been discharged less than one month ago and resided downtown. 51 conforming patients were divided into experimental(ebip intervention) and control groups for a single-blind randomized trial. data were collected using an introductory information form, pulmonary function test(pft), the baseline dyspnea index(bdi), body mass index(bmi) and the self care management process in chronic illness(scmp-g) scale. there were no addition interventions to the control group. the intervention group underwent a 3-month ebip intervention that included education, house visits and follow-ups through phone calls. the data were analyzed using spss version 17.0 with descriptive statistics, x2,mann whitney u and wilcoxon signed-rank tests. p\<0.05 was statistically significant.

Eligibility criteria:
inclusion criteria: * individuals to be included in the study are 18 years of age and over * have been diagnosed with copd stage 2 for six months or more, * not having been in hospital for one month after discharge, - no communication problems, * lack of mental confusion, * conscious and complete orientation * volunteering to participate in the research, * it is planned to be conducted with patients living in the center of kars. exclusion criteria: * being 18 years old and under, * koah stage 1, 2, 4 diagnosed, * being a communication problem, * having mental confusion or * having any psychiatric problem, * not volunteering to participate in the research, * living outside the kars center

Keywords: copd dyspnea self-care management nurse education.
dupilumab efficacy on bronchial inflammation, small airways disfunction and mucous secretion

Conditions: Asthma; Eosinophilic

Summary: unicentric prospective real life study designed to analyse the efficacy of dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group

after patients signed informed consent, before (visit 1), after 4-5 months (visit 2), and after 12 months (visit 3) dupilumab treatment began, the following techniques and measurements will be performed or collected: demographic data, blood analyses (eosinophil counts and total ige), skin prick-test to common aeroallergens (only in the visit 1), asthma control test (act), sino-nasal outcome test (snot-22), test of adherence to inhalers (tai), number of severe asthma exacerbations (in the previous year; in the visit 2, in the previous 4 months), oral and inhaled steroid daily doses received, spirometry, exhaled nitric oxide (feno), pulmonary volumes, carbon monoxide transference, oscillometry, and induced sputum (inflammatory cell counts and mucin profile \[muc1, muc2, muc5ac, muc5b\]). all patients will be performed at visits 1 and 3 in a 3d culture of primary nasal epithelial cells from asthmatic patients the pattern of gene and to identify new soluble biomarkers through quantitative proteomic analysis of culture supernatants. also a chest ct scan with expiratory images will be done only in visits 1 and 3.

Eligibility criteria:
inclusion criteria: * 18 -80 years * severe uncontrolled eosinophilic asthma by gina (global initiative for asthma) criteria * clinical indication of dupilumab exclusion criteria: * smoking over 10 pack/year * treatment with monoclonal antibodies treatment during the previous three months * refuse to sign informed consent
effect of tadalafil on the quality of life and sexual life in erectile dysfunction

Conditions: Impotence; Erectile Dysfunction

Summary: study is a clinical study assessing the effect of oral tadalafil 10mg or 20 mg on psychosocial aspects and quality of life of erectile dysfunction patients and to compare tadalafil with previous oral erectile dysfunction medication. study period is 13 weeks. study patients fill in quality of life questionnaires and treatment satisfaction questionnaires.


Eligibility criteria:
inclusion criteria: * have a history of erectile dysfunction (defined as a consistent change in the quality of erection that adversely affects the patient's satisfaction with sexual intercourse)of at least 3 months duration * have been using any oral prescription medication,but not tadalafil, for erectile dysfunction for a minimum period of 3 months before visit 1 * have responded to previous erectile dysfunction medication as assessed by the investigator exclusion criteria: * exhibit evidence of clinically significant hepatobiliary disease (including jaundice) at visit 1 * cardiovascular exclusion criteria: history of chronic stable angina treated with nitrates, recent acute cardiovascular events or procedures (myocardial infarction, coronary interventions, stroke, etc.), history of other serious cardiovascular events (e.g. arrhythmias, sudden cardiac arrest, congestive heart failure, etc.), systolic blood pressure \<90mmhg or diastolic blood pressure \<50mmhg at screening * receiving treatment with cancer chemotherapy

Keywords: erectile dysfunction tadalafil
effectiveness of repositioning and cranial remolding in infants with cranial deformation

Conditions: Deformational Plagiocephaly; Deformational Posterior Plagiocephaly; Brachycephaly; Torticollis; Congenital Muscular Torticollis

Summary: this study will examine how effective caregiver's repositioning strategies are in correcting an infant's deformational cranial shape, as well as the effectiveness of the use of a custom cranial remolding orthosis for treatment of deformational head shapes. infants with torticollis will be concurrently enrolled in physical therapy treatment until the torticollis is resolved. a normal, unaffected population will be studied to compare typical growth to the growth of infants undergoing active treatment.

infants 2 months of age who have been diagnosed with a deformational head shape will be begin repositioning therapy (and physical therapy if torticollis is present) and be followed at least monthly. at 4, 5, and 6 months of age, if the head shape has not resolved, they will be given the option to pursue treatment with a cranial remolding orthosis. all affected infants will undergo active treatment until the head shape is resolved or the infant is 12 months of age (whichever comes first). normal infants will be evaluated at 2, 6, and 12 months of age and will not be enrolled in any active treatment. all infants will return at 12 months of age for a final evaluation.

Eligibility criteria:
inclusion criteria for control group: * healthy infants with normal physical development and no need for physical therapy intervention exclusion criteria for control group: * infants with abnormal head shapes (plagiocephaly or craniosynostosis) * infants with growth abnormalities (such as genetic conditions) * infants with developmental delay significant to warrant physical therapy or occupational therapy

Keywords: plagiocephaly brachycephaly asymmetrical brachycephaly helmet cranial remolding orthosis repositioning deformational torticollis normal